UK markets closed

ObsEva SA (OBSV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6900-0.1000 (-5.59%)
At close: 04:00PM EST
1.6900 0.00 (0.00%)
After hours: 06:11PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.7900
Open1.7800
Bid1.6800 x 1000
Ask1.7200 x 1400
Day's range1.6500 - 1.8201
52-week range1.6500 - 5.5500
Volume834,293
Avg. volume885,032
Market cap131.772M
Beta (5Y monthly)0.63
PE ratio (TTM)N/A
EPS (TTM)-0.8220
Earnings date03 Mar 2022 - 07 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.75
  • Globe Newswire

    ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

    Figure 1 Response Rate at 3 Months -Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months- -Once daily linzagolix 75 mg without ABT

  • Globe Newswire

    ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference

    GENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright BioConnect Conference, to be held January 10-13, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Monday, January 10, 2022. A webca

  • Globe Newswire

    ObsEva Added to the NASDAQ Biotechnology Index

    GENEVA, Switzerland December 20, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. “We are proud to be included in the prestigious Nasdaq Biotechnology Index,” said Brian O’Callaghan, CEO of ObsEva. “Over the last year, we have made n